Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ farnesoid X receptor (FXR) agonist programme, aimed at treating inflammatory ...

And that's not counting the other nine obesity drugs Lilly's testing in clinical trials. Get top local stories in San Diego delivered to you every morning. Sign up for NBC San Diego's News ...

Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are ... Get top local stories in San Diego delivered to you every morning. Sign up for NBC San Diego's News Headlines newsletter.

The deal sees Lilly pay out $9 million upfront plus another $1 million after 15 months to the San Diego biotech, according to Securities and Exchange Commission (SEC) documents filed Feb. 25.

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE ... today announced that Eli Lilly and Company (NYSE:LLY) (“Lilly”) will acquire Organovo’s FXR program, including its lead asset, FXR314.